Onco Actu du 31 août 2016

	1. Biologie
Retinoic acid suppresses colorectal cancer development [Stanford Medicine] Levels of retinoic acid, a vitamin A metabolite, are low in mice and humans with colorectal cancer, according to new research. People with high levels of an enzyme that degrades retinoic acid have a poor prognosis.
Cancer and Unstable Genomes Linked to Junk DNA Changes [GEN] “What we found is probably the tip of the iceberg. There could be all sorts of functional consequences to having variation within the complex, repetitive portion of the genome that we don’t know about yet.”
	2.8 Etiologie - Contraceptifs, THS
When it comes to menopausal hormone therapy, women are left guessing at the risks [The Guardian] A new study suggests stronger links between MHT and breast cancer. But patchy information means it’s hard to advise my patients properly.
	4.5 Dép., diag. & prono. - Colorectal
When A Screening Test For Colon Cancer Leads To A Pricey Follow-Up [NPR] A stool-based DNA test to screen for colon cancer is available that is readily paid for by health plans, including Medicare. But if I have a positive Cologuard test result, I'd have to pay several hundred dollars for a regular diagnostic colonoscopy. Doesn't this discourage people from getting screened for colon cancer, which is the goal, after all?
	4.9 Dép., diag. & prono. - Sein
Radiologists Detect Breast Cancer in “Blink of an Eye” [Brigham and Women’s Hospital] In a paper published August 29 in the Proceedings of the National Academy of Sciences, visual attention researchers showed radiologists mammograms for half a second and found that they could identify abnormal mammograms at better than chance levels.
	5.2 Pharma
Ariad finishes rolling NDA for lung cancer; wants sped-up review [FierceBiotech] The Cambridge, MA-based company is seeking a license for brigatinib, its investigational anaplastic lymphoma kinase (ALK) inhibitor, to be used when patients cannot take or are resistant to Pfizer’s marketed ALK non-small cell lung cancer drug Xalkori (crizotinib).
The public’s view of pharma just keeps getting worse [STAT] To be specific, just 28 percent of Americans have a positive view of drug makers, while 19 percent reported feeling neutral and 51 percent have a negative view.
	6. Lutte contre les cancers
Tasmanian devils show signs of resistance to devastating facial cancer [Nature] “It has a lot of potential for future vaccination studies,” says Hannah Siddle, a molecular immunologist who is developing vaccines for the disease at the University of Southampton, UK. For instance, vaccinations or immunotherapy that target these genes might help the devils’ immune systems to fight off the cancer.
Chemotherapy warning as hundreds die from cancer fighting drugs [The Telegraph] For the first time researchers looked at the numbers of cancer patients who died within 30 days of starting chemotherapy, which indicates that the medication is the cause of death, rather than the cancer.
	6.10.1 Politiques (USA)
Cancer Moonshot report to land on Sept. 7 [BioCentury] The Blue Ribbon Panel convened to provide advice about the Obama administration's Cancer Moonshot Initiative has finalized its report, according to National Cancer Institute staff.
	6.7.1 Bioinformatique
Google DeepMind and UCLH collaborate on AI-based radiotherapy treatment [The Guardian] Google’s AI research arm is partnering with the hospital to improve the scans available for radiotherapists by using machine learning.
	6.8 Communication
Where are the TV ads to “educate” patients about the negative Opdivo lung cancer trial? [HealthNewsReview] I am looking forward to the television ad that informs patients and their families about the failed trial so that they can have an “informed discussion” with their physicians about it. But, I won’t hold my breath waiting.